| Characteristic | Overall N = 471 |
negative and at risk N = 361 |
positive N = 111 |
p-value2 |
|---|---|---|---|---|
| Age at time of sample (years) | 75 (68, 79) | 74 (67, 79) | 77 (68, 81) | 0.4 |
| Female sex | 22 (47%) | 15 (42%) | 7 (64%) | 0.2 |
| Race | 0.3 | |||
| black/aa | 5 (11%) | 5 (14%) | 0 (0%) | |
| white | 42 (89%) | 31 (86%) | 11 (100%) | |
| Ethnicity | 0.2 | |||
| hispanic/latinx | 1 (2.1%) | 0 (0%) | 1 (9.1%) | |
| not hispanic/latinx | 46 (98%) | 36 (100%) | 10 (91%) | |
| Number of immune-related adverse events (iRAEs) | 2 (1, 3) | 2 (1, 3) | 2 (1, 3) | 0.6 |
| AT1R antibody interpretation | <0.001 | |||
| at risk | 13 (28%) | 13 (36%) | 0 (0%) | |
| negative | 23 (49%) | 23 (64%) | 0 (0%) | |
| positive | 11 (23%) | 0 (0%) | 11 (100%) | |
| Death | 17 (37%) | 13 (37%) | 4 (36%) | >0.9 |
| Heart failure at baseline | 9 (19%) | 6 (17%) | 3 (27%) | 0.4 |
| Heart failure at outcome | 0.6 | |||
| 0 | 33 (70%) | 24 (67%) | 9 (82%) | |
| 1 | 13 (28%) | 11 (31%) | 2 (18%) | |
| 1 (recovered then HFrEF after ICI) | 1 (2.1%) | 1 (2.8%) | 0 (0%) | |
| Arrhythmia at baseline | >0.9 | |||
| 0 | 31 (66%) | 24 (67%) | 7 (64%) | |
| 1 | 16 (34%) | 12 (33%) | 4 (36%) | |
| Arrhythmia at outcome | 0.7 | |||
| 0 | 26 (55%) | 19 (53%) | 7 (64%) | |
| 1 | 21 (45%) | 17 (47%) | 4 (36%) | |
| New arrhythmia | 17 (36%) | 13 (36%) | 4 (36%) | >0.9 |
| ACE inhibitor or ARB use | 0.060 | |||
| 0 | 29 (62%) | 19 (53%) | 10 (91%) | |
| 0 on admission, started lisinopril 3/17/2022 | 1 (2.1%) | 1 (2.8%) | 0 (0%) | |
| 1 | 17 (36%) | 16 (44%) | 1 (9.1%) | |
| Spironolactone (aldactone) use | 1 (2.1%) | 1 (2.8%) | 0 (0%) | >0.9 |
| SGLT2 inhibitor use | 3 (6.4%) | 3 (8.3%) | 0 (0%) | >0.9 |
| Beta-blocker use | 0.8 | |||
| 0 | 25 (53%) | 18 (50%) | 7 (64%) | |
| 1 | 20 (43%) | 16 (44%) | 4 (36%) | |
| 1 (atenolol) | 1 (2.1%) | 1 (2.8%) | 0 (0%) | |
| 1 (nadolol) | 1 (2.1%) | 1 (2.8%) | 0 (0%) | |
| myocarditis_severty_adjudication | >0.9 | |||
| 1 | 3 (6.4%) | 2 (5.6%) | 1 (9.1%) | |
| 1 (asx) | 1 (2.1%) | 1 (2.8%) | 0 (0%) | |
| 1 (hypotension but likely 2/2 to other conditions) | 1 (2.1%) | 0 (0%) | 1 (9.1%) | |
| 2 | 3 (6.4%) | 2 (5.6%) | 1 (9.1%) | |
| 2 (cardiac MRI with signs of prior myocarditis but not active) | 1 (2.1%) | 1 (2.8%) | 0 (0%) | |
| 2 (had cMRI that does not seem conclusive for myocarditis, had CP) | 1 (2.1%) | 1 (2.8%) | 0 (0%) | |
| 2 (Had CP but likely due to pericardial effusion) | 1 (2.1%) | 1 (2.8%) | 0 (0%) | |
| 2 (mildly reduced EF but no clear sx) | 1 (2.1%) | 1 (2.8%) | 0 (0%) | |
| 2 (new DOE) | 1 (2.1%) | 0 (0%) | 1 (9.1%) | |
| 2 (normal echo, ? cardiogenic syncope) | 1 (2.1%) | 0 (0%) | 1 (9.1%) | |
| 2 (unstable but for other reasons) | 1 (2.1%) | 1 (2.8%) | 0 (0%) | |
| 2/3 (Formal MRI didn't read myocarditis, but per notes Dr. Kwan thought was consistent) | 1 (2.1%) | 1 (2.8%) | 0 (0%) | |
| 3 | 17 (36%) | 12 (33%) | 5 (45%) | |
| 3 (based on MRI) | 1 (2.1%) | 1 (2.8%) | 0 (0%) | |
| 3 (cMRI 11/2022 with myocarditis) | 1 (2.1%) | 1 (2.8%) | 0 (0%) | |
| 3 (cMRI suggestive and TTE with known apical akinesis iso scar) | 1 (2.1%) | 1 (2.8%) | 0 (0%) | |
| 3 (EF 25 - 30% w/ sx but no instability) | 1 (2.1%) | 1 (2.8%) | 0 (0%) | |
| 3 (EF drop w/ CP but no instability) | 1 (2.1%) | 1 (2.8%) | 0 (0%) | |
| 3 (In MICU but for AHRF 2/2 lung dz) | 1 (2.1%) | 1 (2.8%) | 0 (0%) | |
| 3 (MRI read equivocal but seems real enough) | 1 (2.1%) | 1 (2.8%) | 0 (0%) | |
| 4 | 6 (13%) | 5 (14%) | 1 (9.1%) | |
| 4 (aggressively worsening trops despite immunosupp, hypotension likely iso sepsis but seems like grade 4) | 1 (2.1%) | 1 (2.8%) | 0 (0%) | |
| Prolonged immunosuppression | 27 (61%) | 18 (51%) | 9 (100%) | 0.008 |
| Number of non-HLA positive beads | 4 (1, 12) | 4 (1, 8) | 23 (15, 29) | 0.004 |
| Metastatic cancer | 11 (69%) | 8 (62%) | 3 (100%) | 0.5 |
| Hypertension | 44 (94%) | 35 (97%) | 9 (82%) | 0.13 |
| Hyperlipidemia | 39 (83%) | 29 (81%) | 10 (91%) | 0.7 |
| Coronary artery disease | 30 (64%) | 21 (58%) | 9 (82%) | 0.3 |
| Diabetes mellitus | 10 (21%) | 9 (25%) | 1 (9.1%) | 0.4 |
| Heart failure | 15 (32%) | 11 (31%) | 4 (36%) | 0.7 |
| Valvular disease | 2 (4.3%) | 2 (5.6%) | 0 (0%) | >0.9 |
| Ipilimumab (IPI) | 11 (23%) | 7 (19%) | 4 (36%) | 0.3 |
| Nivolumab (NIVO) | 18 (38%) | 14 (39%) | 4 (36%) | >0.9 |
| Pembrolizumab (PEMBRO) | 23 (49%) | 16 (44%) | 7 (64%) | 0.3 |
| Durvalumab (DURVA) | 5 (11%) | 3 (8.3%) | 2 (18%) | 0.6 |
| Atezolizumab (ATEZO) | 4 (8.5%) | 4 (11%) | 0 (0%) | 0.6 |
| Days from initial ICI exposure to presentation | 57 (33, 204) | 56 (32, 194) | 82 (39, 805) | 0.3 |
| Pulse-dose steroids given | 45 (96%) | 35 (97%) | 10 (91%) | 0.4 |
| Prolonged steroid course after pulse | 24 (51%) | 17 (47%) | 7 (64%) | 0.3 |
| Mycophenolate mofetil (MMF) | 28 (60%) | 21 (58%) | 7 (64%) | >0.9 |
| Abatacept | 19 (40%) | 14 (39%) | 5 (45%) | 0.7 |
| IVIG | 12 (26%) | 7 (19%) | 5 (45%) | 0.12 |
| Infliximab | 2 (4.3%) | 2 (5.6%) | 0 (0%) | >0.9 |
| Tofacitinib | 14 (30%) | 12 (33%) | 2 (18%) | 0.5 |
| Any immunosuppression escalation | 27 (57%) | 18 (50%) | 9 (82%) | 0.086 |
| Number of immunosuppression escalations | 1.00 (0.00, 1.00) | 1.00 (0.00, 1.00) | 1.00 (1.00, 2.00) | 0.10 |
| LVEF (%) — clinical | 58 (48, 63) | 54 (39, 61) | 64 (58, 64) | 0.036 |
| RVEF (%) — clinical | 49 (45, 56) | 49 (44, 52) | 58 (50, 66) | 0.078 |
| Cardiomyopathy etiology | 0.2 | |||
| 9 (23%) | 6 (20%) | 3 (33%) | ||
| 0 | 1 (2.6%) | 1 (3.3%) | 0 (0%) | |
| both | 2 (5.1%) | 1 (3.3%) | 1 (11%) | |
| ischemic | 1 (2.6%) | 1 (3.3%) | 0 (0%) | |
| ischemic_nonischemic_both_sheet_4 | 3 (7.7%) | 1 (3.3%) | 2 (22%) | |
| nonischemic | 23 (59%) | 20 (67%) | 3 (33%) | |
| Other irAEs | 0.4 | |||
| 45 (96%) | 35 (97%) | 10 (91%) | ||
| myositis, MG myocarditis | 1 (2.1%) | 0 (0%) | 1 (9.1%) | |
| pneumonitis | 1 (2.1%) | 1 (2.8%) | 0 (0%) | |
| Native T1, CMR (ms) | 992 (961, 1,016) | 1,012 (973, 1,016) | 953 (938, 977) | 0.11 |
| ECV, CMR (%) — categories | 29.0 (24.5, 35.5) | 31.0 (26.0, 35.0) | 26.0 (23.0, 40.0) | >0.9 |
| T2 (0=normal, 1=elevated) | 19 (56%) | 14 (56%) | 5 (56%) | >0.9 |
| matt_for_sure_ischemic_lge | 1 (25%) | 1 (33%) | 0 (0%) | >0.9 |
| LGE burden, CMR (% LV mass) | 7 (3, 12) | 7 (3, 10) | 11 (4, 15) | 0.4 |
| CM outcome (1 = event) | 14 (88%) | 13 (93%) | 1 (50%) | 0.2 |
| LVEF, CMR (%) | 59 (52, 64) | 58 (44, 63) | 64 (58, 68) | 0.078 |
| RVEF, CMR (%) | 52 (48, 56) | 52 (48, 54) | 54 (50, 58) | 0.2 |
| LV wall thickness (AP), mm | 10.00 (8.00, 11.00) | 10.00 (8.00, 11.00) | 9.00 (6.00, 11.00) | 0.3 |
| LV wall thickness (PL), mm | 8.00 (7.00, 10.00) | 8.00 (6.00, 9.00) | 9.00 (7.00, 11.00) | 0.3 |
| Global radial strain, CMR (%) | 26 (21, 36) | 23 (20, 31) | 35 (24, 37) | 0.10 |
| Global circumferential strain, CMR (%) | -17.7 (-20.0, -13.9) | -15.2 (-18.3, -13.5) | -18.8 (-20.2, -15.3) | 0.2 |
| Global longitudinal strain (GLS), CMR (%) | -13.5 (-16.6, -10.7) | -13.1 (-16.6, -10.0) | -15.1 (-15.5, -10.8) | 0.6 |
| Abnormal GLS | 32 (84%) | 23 (85%) | 9 (82%) | >0.9 |
| MAPSE — anterior (mm) | 10.2 (7.3, 12.4) | 10.0 (6.7, 13.6) | 10.2 (7.3, 12.2) | >0.9 |
| MAPSE — inferior (mm) | 11.7 (9.8, 14.6) | 12.3 (9.6, 14.7) | 10.8 (9.8, 13.3) | 0.7 |
| MAPSE — mean (mm) | 10.9 (8.0, 12.8) | 10.2 (7.7, 13.6) | 11.3 (8.7, 12.3) | 0.8 |
| remove_variavle | NA (NA, NA) | NA (NA, NA) | NA (NA, NA) | |
| 1 Median (Q1, Q3); n (%) | ||||
| 2 Wilcoxon rank sum test; Pearson’s Chi-squared test; Fisher’s exact test; NA | ||||
initialization_att1r_project
Quarto
Positive vs non-positive
Negative vs non-negative
| Characteristic | Overall N = 471 |
negative N = 231 |
positive and at risk N = 241 |
p-value2 |
|---|---|---|---|---|
| Age at time of sample (years) | 75 (68, 79) | 75 (69, 80) | 73 (65, 79) | 0.5 |
| Female sex | 22 (47%) | 9 (39%) | 13 (54%) | 0.3 |
| Race | 0.2 | |||
| black/aa | 5 (11%) | 4 (17%) | 1 (4.2%) | |
| white | 42 (89%) | 19 (83%) | 23 (96%) | |
| Ethnicity | >0.9 | |||
| hispanic/latinx | 1 (2.1%) | 0 (0%) | 1 (4.2%) | |
| not hispanic/latinx | 46 (98%) | 23 (100%) | 23 (96%) | |
| Number of immune-related adverse events (iRAEs) | 2 (1, 3) | 2 (1, 3) | 2 (1, 3) | 0.6 |
| AT1R antibody interpretation | <0.001 | |||
| at risk | 13 (28%) | 0 (0%) | 13 (54%) | |
| negative | 23 (49%) | 23 (100%) | 0 (0%) | |
| positive | 11 (23%) | 0 (0%) | 11 (46%) | |
| Death | 17 (37%) | 9 (39%) | 8 (35%) | 0.8 |
| Heart failure at baseline | 9 (19%) | 4 (17%) | 5 (21%) | >0.9 |
| Heart failure at outcome | 0.4 | |||
| 0 | 33 (70%) | 15 (65%) | 18 (75%) | |
| 1 | 13 (28%) | 8 (35%) | 5 (21%) | |
| 1 (recovered then HFrEF after ICI) | 1 (2.1%) | 0 (0%) | 1 (4.2%) | |
| Arrhythmia at baseline | >0.9 | |||
| 0 | 31 (66%) | 15 (65%) | 16 (67%) | |
| 1 | 16 (34%) | 8 (35%) | 8 (33%) | |
| Arrhythmia at outcome | 0.9 | |||
| 0 | 26 (55%) | 13 (57%) | 13 (54%) | |
| 1 | 21 (45%) | 10 (43%) | 11 (46%) | |
| New arrhythmia | 17 (36%) | 8 (35%) | 9 (38%) | 0.8 |
| ACE inhibitor or ARB use | 0.6 | |||
| 0 | 29 (62%) | 13 (57%) | 16 (67%) | |
| 0 on admission, started lisinopril 3/17/2022 | 1 (2.1%) | 1 (4.3%) | 0 (0%) | |
| 1 | 17 (36%) | 9 (39%) | 8 (33%) | |
| Spironolactone (aldactone) use | 1 (2.1%) | 0 (0%) | 1 (4.2%) | >0.9 |
| SGLT2 inhibitor use | 3 (6.4%) | 3 (13%) | 0 (0%) | 0.11 |
| Beta-blocker use | 0.6 | |||
| 0 | 25 (53%) | 11 (48%) | 14 (58%) | |
| 1 | 20 (43%) | 10 (43%) | 10 (42%) | |
| 1 (atenolol) | 1 (2.1%) | 1 (4.3%) | 0 (0%) | |
| 1 (nadolol) | 1 (2.1%) | 1 (4.3%) | 0 (0%) | |
| myocarditis_severty_adjudication | 0.5 | |||
| 1 | 3 (6.4%) | 2 (8.7%) | 1 (4.2%) | |
| 1 (asx) | 1 (2.1%) | 1 (4.3%) | 0 (0%) | |
| 1 (hypotension but likely 2/2 to other conditions) | 1 (2.1%) | 0 (0%) | 1 (4.2%) | |
| 2 | 3 (6.4%) | 2 (8.7%) | 1 (4.2%) | |
| 2 (cardiac MRI with signs of prior myocarditis but not active) | 1 (2.1%) | 1 (4.3%) | 0 (0%) | |
| 2 (had cMRI that does not seem conclusive for myocarditis, had CP) | 1 (2.1%) | 0 (0%) | 1 (4.2%) | |
| 2 (Had CP but likely due to pericardial effusion) | 1 (2.1%) | 0 (0%) | 1 (4.2%) | |
| 2 (mildly reduced EF but no clear sx) | 1 (2.1%) | 0 (0%) | 1 (4.2%) | |
| 2 (new DOE) | 1 (2.1%) | 0 (0%) | 1 (4.2%) | |
| 2 (normal echo, ? cardiogenic syncope) | 1 (2.1%) | 0 (0%) | 1 (4.2%) | |
| 2 (unstable but for other reasons) | 1 (2.1%) | 0 (0%) | 1 (4.2%) | |
| 2/3 (Formal MRI didn't read myocarditis, but per notes Dr. Kwan thought was consistent) | 1 (2.1%) | 1 (4.3%) | 0 (0%) | |
| 3 | 17 (36%) | 8 (35%) | 9 (38%) | |
| 3 (based on MRI) | 1 (2.1%) | 0 (0%) | 1 (4.2%) | |
| 3 (cMRI 11/2022 with myocarditis) | 1 (2.1%) | 0 (0%) | 1 (4.2%) | |
| 3 (cMRI suggestive and TTE with known apical akinesis iso scar) | 1 (2.1%) | 1 (4.3%) | 0 (0%) | |
| 3 (EF 25 - 30% w/ sx but no instability) | 1 (2.1%) | 1 (4.3%) | 0 (0%) | |
| 3 (EF drop w/ CP but no instability) | 1 (2.1%) | 0 (0%) | 1 (4.2%) | |
| 3 (In MICU but for AHRF 2/2 lung dz) | 1 (2.1%) | 0 (0%) | 1 (4.2%) | |
| 3 (MRI read equivocal but seems real enough) | 1 (2.1%) | 1 (4.3%) | 0 (0%) | |
| 4 | 6 (13%) | 5 (22%) | 1 (4.2%) | |
| 4 (aggressively worsening trops despite immunosupp, hypotension likely iso sepsis but seems like grade 4) | 1 (2.1%) | 0 (0%) | 1 (4.2%) | |
| Prolonged immunosuppression | 27 (61%) | 11 (50%) | 16 (73%) | 0.12 |
| Number of non-HLA positive beads | 4 (1, 12) | 1 (1, 5) | 10 (4, 16) | 0.024 |
| Metastatic cancer | 11 (69%) | 5 (50%) | 6 (100%) | 0.093 |
| Hypertension | 44 (94%) | 23 (100%) | 21 (88%) | 0.2 |
| Hyperlipidemia | 39 (83%) | 18 (78%) | 21 (88%) | 0.5 |
| Coronary artery disease | 30 (64%) | 16 (70%) | 14 (58%) | 0.4 |
| Diabetes mellitus | 10 (21%) | 7 (30%) | 3 (13%) | 0.2 |
| Heart failure | 15 (32%) | 7 (30%) | 8 (33%) | 0.8 |
| Valvular disease | 2 (4.3%) | 2 (8.7%) | 0 (0%) | 0.2 |
| Ipilimumab (IPI) | 11 (23%) | 3 (13%) | 8 (33%) | 0.10 |
| Nivolumab (NIVO) | 18 (38%) | 8 (35%) | 10 (42%) | 0.6 |
| Pembrolizumab (PEMBRO) | 23 (49%) | 11 (48%) | 12 (50%) | 0.9 |
| Durvalumab (DURVA) | 5 (11%) | 2 (8.7%) | 3 (13%) | >0.9 |
| Atezolizumab (ATEZO) | 4 (8.5%) | 2 (8.7%) | 2 (8.3%) | >0.9 |
| Days from initial ICI exposure to presentation | 57 (33, 204) | 53 (34, 145) | 57 (31, 276) | 0.7 |
| Pulse-dose steroids given | 45 (96%) | 22 (96%) | 23 (96%) | >0.9 |
| Prolonged steroid course after pulse | 24 (51%) | 12 (52%) | 12 (50%) | 0.9 |
| Mycophenolate mofetil (MMF) | 28 (60%) | 15 (65%) | 13 (54%) | 0.4 |
| Abatacept | 19 (40%) | 10 (43%) | 9 (38%) | 0.7 |
| IVIG | 12 (26%) | 5 (22%) | 7 (29%) | 0.6 |
| Infliximab | 2 (4.3%) | 2 (8.7%) | 0 (0%) | 0.2 |
| Tofacitinib | 14 (30%) | 8 (35%) | 6 (25%) | 0.5 |
| Any immunosuppression escalation | 27 (57%) | 11 (48%) | 16 (67%) | 0.2 |
| Number of immunosuppression escalations | 1.00 (0.00, 1.00) | 1.00 (0.00, 1.00) | 1.00 (0.00, 1.00) | 0.3 |
| LVEF (%) — clinical | 58 (48, 63) | 54 (41, 59) | 58 (48, 64) | 0.2 |
| RVEF (%) — clinical | 49 (45, 56) | 46 (39, 50) | 52 (49, 63) | 0.015 |
| Cardiomyopathy etiology | 0.7 | |||
| 9 (23%) | 5 (26%) | 4 (20%) | ||
| 0 | 1 (2.6%) | 1 (5.3%) | 0 (0%) | |
| both | 2 (5.1%) | 0 (0%) | 2 (10%) | |
| ischemic | 1 (2.6%) | 1 (5.3%) | 0 (0%) | |
| ischemic_nonischemic_both_sheet_4 | 3 (7.7%) | 1 (5.3%) | 2 (10%) | |
| nonischemic | 23 (59%) | 11 (58%) | 12 (60%) | |
| Other irAEs | >0.9 | |||
| 45 (96%) | 22 (96%) | 23 (96%) | ||
| myositis, MG myocarditis | 1 (2.1%) | 0 (0%) | 1 (4.2%) | |
| pneumonitis | 1 (2.1%) | 1 (4.3%) | 0 (0%) | |
| Native T1, CMR (ms) | 992 (961, 1,016) | 1,002 (982, 1,016) | 971 (946, 1,042) | 0.5 |
| ECV, CMR (%) — categories | 29.0 (24.5, 35.5) | 31.0 (26.0, 36.0) | 28.5 (23.0, 34.0) | 0.7 |
| T2 (0=normal, 1=elevated) | 19 (56%) | 9 (50%) | 10 (63%) | 0.5 |
| matt_for_sure_ischemic_lge | 1 (25%) | 1 (33%) | 0 (0%) | >0.9 |
| LGE burden, CMR (% LV mass) | 7 (3, 12) | 7 (0, 10) | 8 (4, 13) | 0.7 |
| CM outcome (1 = event) | 14 (88%) | 7 (88%) | 7 (88%) | >0.9 |
| LVEF, CMR (%) | 59 (52, 64) | 60 (49, 63) | 59 (52, 68) | 0.5 |
| RVEF, CMR (%) | 52 (48, 56) | 52 (49, 54) | 52 (48, 58) | 0.8 |
| LV wall thickness (AP), mm | 10.00 (8.00, 11.00) | 10.00 (8.00, 11.00) | 10.50 (8.00, 11.00) | 0.6 |
| LV wall thickness (PL), mm | 8.00 (7.00, 10.00) | 8.00 (6.00, 9.00) | 8.00 (7.00, 10.00) | 0.4 |
| Global radial strain, CMR (%) | 26 (21, 36) | 29 (20, 34) | 24 (21, 36) | 0.7 |
| Global circumferential strain, CMR (%) | -17.7 (-20.0, -13.9) | -17.8 (-20.3, -13.0) | -15.3 (-19.8, -14.2) | >0.9 |
| Global longitudinal strain (GLS), CMR (%) | -13.5 (-16.6, -10.7) | -14.4 (-17.9, -11.9) | -12.1 (-15.3, -9.6) | 0.2 |
| Abnormal GLS | 32 (84%) | 14 (82%) | 18 (86%) | >0.9 |
| MAPSE — anterior (mm) | 10.2 (7.3, 12.4) | 10.6 (6.3, 14.4) | 9.5 (7.3, 11.9) | 0.3 |
| MAPSE — inferior (mm) | 11.7 (9.8, 14.6) | 13.6 (10.2, 14.6) | 10.7 (9.4, 13.8) | 0.3 |
| MAPSE — mean (mm) | 10.9 (8.0, 12.8) | 12.2 (7.1, 14.4) | 10.1 (8.3, 12.3) | 0.4 |
| remove_variavle | NA (NA, NA) | NA (NA, NA) | NA (NA, NA) | |
| 1 Median (Q1, Q3); n (%) | ||||
| 2 Wilcoxon rank sum test; Pearson’s Chi-squared test; Fisher’s exact test; NA | ||||
Removed all “at risk”
| Characteristic | Overall N = 341 |
negative N = 231 |
positive N = 111 |
p-value2 |
|---|---|---|---|---|
| Age at time of sample (years) | 76 (69, 80) | 75 (69, 80) | 77 (68, 81) | 0.8 |
| Female sex | 16 (47%) | 9 (39%) | 7 (64%) | 0.2 |
| Race | 0.3 | |||
| black/aa | 4 (12%) | 4 (17%) | 0 (0%) | |
| white | 30 (88%) | 19 (83%) | 11 (100%) | |
| Ethnicity | 0.3 | |||
| hispanic/latinx | 1 (2.9%) | 0 (0%) | 1 (9.1%) | |
| not hispanic/latinx | 33 (97%) | 23 (100%) | 10 (91%) | |
| Number of immune-related adverse events (iRAEs) | 2 (1, 3) | 2 (1, 3) | 2 (1, 3) | >0.9 |
| AT1R antibody interpretation | <0.001 | |||
| negative | 23 (68%) | 23 (100%) | 0 (0%) | |
| positive | 11 (32%) | 0 (0%) | 11 (100%) | |
| Death | 13 (38%) | 9 (39%) | 4 (36%) | >0.9 |
| Heart failure at baseline | 7 (21%) | 4 (17%) | 3 (27%) | 0.7 |
| Heart failure at outcome | 0.4 | |||
| 0 | 24 (71%) | 15 (65%) | 9 (82%) | |
| 1 | 10 (29%) | 8 (35%) | 2 (18%) | |
| Arrhythmia at baseline | >0.9 | |||
| 0 | 22 (65%) | 15 (65%) | 7 (64%) | |
| 1 | 12 (35%) | 8 (35%) | 4 (36%) | |
| Arrhythmia at outcome | >0.9 | |||
| 0 | 20 (59%) | 13 (57%) | 7 (64%) | |
| 1 | 14 (41%) | 10 (43%) | 4 (36%) | |
| New arrhythmia | 12 (35%) | 8 (35%) | 4 (36%) | >0.9 |
| ACE inhibitor or ARB use | 0.14 | |||
| 0 | 23 (68%) | 13 (57%) | 10 (91%) | |
| 0 on admission, started lisinopril 3/17/2022 | 1 (2.9%) | 1 (4.3%) | 0 (0%) | |
| 1 | 10 (29%) | 9 (39%) | 1 (9.1%) | |
| Spironolactone (aldactone) use | ||||
| 0 | 34 (100%) | 23 (100%) | 11 (100%) | |
| SGLT2 inhibitor use | 3 (8.8%) | 3 (13%) | 0 (0%) | 0.5 |
| Beta-blocker use | 0.9 | |||
| 0 | 18 (53%) | 11 (48%) | 7 (64%) | |
| 1 | 14 (41%) | 10 (43%) | 4 (36%) | |
| 1 (atenolol) | 1 (2.9%) | 1 (4.3%) | 0 (0%) | |
| 1 (nadolol) | 1 (2.9%) | 1 (4.3%) | 0 (0%) | |
| myocarditis_severty_adjudication | 0.8 | |||
| 1 | 3 (8.8%) | 2 (8.7%) | 1 (9.1%) | |
| 1 (asx) | 1 (2.9%) | 1 (4.3%) | 0 (0%) | |
| 1 (hypotension but likely 2/2 to other conditions) | 1 (2.9%) | 0 (0%) | 1 (9.1%) | |
| 2 | 3 (8.8%) | 2 (8.7%) | 1 (9.1%) | |
| 2 (cardiac MRI with signs of prior myocarditis but not active) | 1 (2.9%) | 1 (4.3%) | 0 (0%) | |
| 2 (new DOE) | 1 (2.9%) | 0 (0%) | 1 (9.1%) | |
| 2 (normal echo, ? cardiogenic syncope) | 1 (2.9%) | 0 (0%) | 1 (9.1%) | |
| 2/3 (Formal MRI didn't read myocarditis, but per notes Dr. Kwan thought was consistent) | 1 (2.9%) | 1 (4.3%) | 0 (0%) | |
| 3 | 13 (38%) | 8 (35%) | 5 (45%) | |
| 3 (cMRI suggestive and TTE with known apical akinesis iso scar) | 1 (2.9%) | 1 (4.3%) | 0 (0%) | |
| 3 (EF 25 - 30% w/ sx but no instability) | 1 (2.9%) | 1 (4.3%) | 0 (0%) | |
| 3 (MRI read equivocal but seems real enough) | 1 (2.9%) | 1 (4.3%) | 0 (0%) | |
| 4 | 6 (18%) | 5 (22%) | 1 (9.1%) | |
| Prolonged immunosuppression | 20 (65%) | 11 (50%) | 9 (100%) | 0.012 |
| Number of non-HLA positive beads | 5 (1, 17) | 1 (1, 5) | 23 (15, 29) | 0.010 |
| Metastatic cancer | 8 (62%) | 5 (50%) | 3 (100%) | 0.2 |
| Hypertension | 32 (94%) | 23 (100%) | 9 (82%) | 0.10 |
| Hyperlipidemia | 28 (82%) | 18 (78%) | 10 (91%) | 0.6 |
| Coronary artery disease | 25 (74%) | 16 (70%) | 9 (82%) | 0.7 |
| Diabetes mellitus | 8 (24%) | 7 (30%) | 1 (9.1%) | 0.2 |
| Heart failure | 11 (32%) | 7 (30%) | 4 (36%) | >0.9 |
| Valvular disease | 2 (5.9%) | 2 (8.7%) | 0 (0%) | >0.9 |
| Ipilimumab (IPI) | 7 (21%) | 3 (13%) | 4 (36%) | 0.2 |
| Nivolumab (NIVO) | 12 (35%) | 8 (35%) | 4 (36%) | >0.9 |
| Pembrolizumab (PEMBRO) | 18 (53%) | 11 (48%) | 7 (64%) | 0.4 |
| Durvalumab (DURVA) | 4 (12%) | 2 (8.7%) | 2 (18%) | 0.6 |
| Atezolizumab (ATEZO) | 2 (5.9%) | 2 (8.7%) | 0 (0%) | >0.9 |
| Days from initial ICI exposure to presentation | 57 (35, 269) | 53 (34, 145) | 82 (39, 805) | 0.4 |
| Pulse-dose steroids given | 32 (94%) | 22 (96%) | 10 (91%) | >0.9 |
| Prolonged steroid course after pulse | 19 (56%) | 12 (52%) | 7 (64%) | 0.7 |
| Mycophenolate mofetil (MMF) | 22 (65%) | 15 (65%) | 7 (64%) | >0.9 |
| Abatacept | 15 (44%) | 10 (43%) | 5 (45%) | >0.9 |
| IVIG | 10 (29%) | 5 (22%) | 5 (45%) | 0.2 |
| Infliximab | 2 (5.9%) | 2 (8.7%) | 0 (0%) | >0.9 |
| Tofacitinib | 10 (29%) | 8 (35%) | 2 (18%) | 0.4 |
| Any immunosuppression escalation | 20 (59%) | 11 (48%) | 9 (82%) | 0.076 |
| Number of immunosuppression escalations | 1.00 (0.00, 1.00) | 1.00 (0.00, 1.00) | 1.00 (1.00, 2.00) | 0.12 |
| LVEF (%) — clinical | 58 (54, 62) | 54 (41, 59) | 64 (58, 64) | 0.023 |
| RVEF (%) — clinical | 49 (44, 52) | 46 (39, 50) | 58 (50, 66) | 0.040 |
| Cardiomyopathy etiology | 0.3 | |||
| 8 (29%) | 5 (26%) | 3 (33%) | ||
| 0 | 1 (3.6%) | 1 (5.3%) | 0 (0%) | |
| both | 1 (3.6%) | 0 (0%) | 1 (11%) | |
| ischemic | 1 (3.6%) | 1 (5.3%) | 0 (0%) | |
| ischemic_nonischemic_both_sheet_4 | 3 (11%) | 1 (5.3%) | 2 (22%) | |
| nonischemic | 14 (50%) | 11 (58%) | 3 (33%) | |
| Other irAEs | 0.5 | |||
| 32 (94%) | 22 (96%) | 10 (91%) | ||
| myositis, MG myocarditis | 1 (2.9%) | 0 (0%) | 1 (9.1%) | |
| pneumonitis | 1 (2.9%) | 1 (4.3%) | 0 (0%) | |
| Native T1, CMR (ms) | 991 (957, 1,015) | 1,002 (982, 1,016) | 953 (938, 977) | 0.2 |
| ECV, CMR (%) — categories | 27.0 (26.0, 36.0) | 31.0 (26.0, 36.0) | 26.0 (23.0, 40.0) | >0.9 |
| T2 (0=normal, 1=elevated) | 14 (52%) | 9 (50%) | 5 (56%) | >0.9 |
| matt_for_sure_ischemic_lge | 1 (25%) | 1 (33%) | 0 (0%) | >0.9 |
| LGE burden, CMR (% LV mass) | 8 (0, 14) | 7 (0, 10) | 11 (4, 15) | 0.4 |
| CM outcome (1 = event) | 8 (80%) | 7 (88%) | 1 (50%) | 0.4 |
| LVEF, CMR (%) | 60 (54, 64) | 60 (49, 63) | 64 (58, 68) | 0.11 |
| RVEF, CMR (%) | 52 (49, 57) | 52 (49, 54) | 54 (50, 58) | 0.3 |
| LV wall thickness (AP), mm | 10.00 (7.00, 11.00) | 10.00 (8.00, 11.00) | 9.00 (6.00, 11.00) | 0.6 |
| LV wall thickness (PL), mm | 8.00 (6.00, 10.00) | 8.00 (6.00, 9.00) | 9.00 (7.00, 11.00) | 0.3 |
| Global radial strain, CMR (%) | 29 (22, 36) | 29 (20, 34) | 35 (24, 37) | 0.2 |
| Global circumferential strain, CMR (%) | -18.1 (-20.2, -14.8) | -17.8 (-20.3, -13.0) | -18.8 (-20.2, -15.3) | 0.3 |
| Global longitudinal strain (GLS), CMR (%) | -14.7 (-16.7, -11.9) | -14.4 (-17.9, -11.9) | -15.1 (-15.5, -10.8) | >0.9 |
| Abnormal GLS | 23 (82%) | 14 (82%) | 9 (82%) | >0.9 |
| MAPSE — anterior (mm) | 10.4 (7.3, 13.4) | 10.6 (6.3, 14.4) | 10.2 (7.3, 12.2) | 0.6 |
| MAPSE — inferior (mm) | 12.4 (9.9, 14.5) | 13.6 (10.2, 14.6) | 10.8 (9.8, 13.3) | 0.4 |
| MAPSE — mean (mm) | 11.7 (8.6, 13.6) | 12.2 (7.1, 14.4) | 11.3 (8.7, 12.3) | 0.8 |
| remove_variavle | NA (NA, NA) | NA (NA, NA) | NA (NA, NA) | |
| 1 Median (Q1, Q3); n (%) | ||||
| 2 Wilcoxon rank sum test; Pearson’s Chi-squared test; Fisher’s exact test; NA; Wilcoxon rank sum exact test | ||||
Clean table for abstract
| Characteristic | Overall N = 341 |
negative N = 231 |
positive N = 111 |
p-value2 |
|---|---|---|---|---|
| Age at time of sample (years) | 76 (69, 80) | 75 (69, 80) | 77 (68, 81) | 0.8 |
| Female sex | 16 (47%) | 9 (39%) | 7 (64%) | 0.2 |
| Race | 0.3 | |||
| black/aa | 4 (12%) | 4 (17%) | 0 (0%) | |
| white | 30 (88%) | 19 (83%) | 11 (100%) | |
| Ethnicity | 0.3 | |||
| hispanic/latinx | 1 (2.9%) | 0 (0%) | 1 (9.1%) | |
| not hispanic/latinx | 33 (97%) | 23 (100%) | 10 (91%) | |
| Death | 13 (38%) | 9 (39%) | 4 (36%) | >0.9 |
| Prolonged immunosuppression | 20 (65%) | 11 (50%) | 9 (100%) | 0.012 |
| Number of non-HLA positive beads | 5 (1, 17) | 1 (1, 5) | 23 (15, 29) | 0.010 |
| Hypertension | 32 (94%) | 23 (100%) | 9 (82%) | 0.10 |
| Hyperlipidemia | 28 (82%) | 18 (78%) | 10 (91%) | 0.6 |
| Coronary artery disease | 25 (74%) | 16 (70%) | 9 (82%) | 0.7 |
| Diabetes mellitus | 8 (24%) | 7 (30%) | 1 (9.1%) | 0.2 |
| Heart failure | 11 (32%) | 7 (30%) | 4 (36%) | >0.9 |
| LGE burden, CMR (% LV mass) | 8 (0, 14) | 7 (0, 10) | 11 (4, 15) | 0.4 |
| LVEF, CMR (%) | 60 (54, 64) | 60 (49, 63) | 64 (58, 68) | 0.11 |
| RVEF, CMR (%) | 52 (49, 57) | 52 (49, 54) | 54 (50, 58) | 0.3 |
| LV wall thickness (AP), mm | 10.00 (7.00, 11.00) | 10.00 (8.00, 11.00) | 9.00 (6.00, 11.00) | 0.6 |
| LV wall thickness (PL), mm | 8.00 (6.00, 10.00) | 8.00 (6.00, 9.00) | 9.00 (7.00, 11.00) | 0.3 |
| Global radial strain, CMR (%) | 29 (22, 36) | 29 (20, 34) | 35 (24, 37) | 0.2 |
| Global circumferential strain, CMR (%) | -18.1 (-20.2, -14.8) | -17.8 (-20.3, -13.0) | -18.8 (-20.2, -15.3) | 0.3 |
| Global longitudinal strain (GLS), CMR (%) | -14.7 (-16.7, -11.9) | -14.4 (-17.9, -11.9) | -15.1 (-15.5, -10.8) | >0.9 |
| Abnormal GLS | 23 (82%) | 14 (82%) | 9 (82%) | >0.9 |
| 1 Median (Q1, Q3); n (%) | ||||
| 2 Wilcoxon rank sum test; Pearson’s Chi-squared test; Fisher’s exact test | ||||
Comparison by immunosupression escalation variable
| Characteristic | Overall N = 471 |
no escalation N = 201 |
yes escalation N = 271 |
p-value2 |
|---|---|---|---|---|
| Age at time of sample (years) | 75 (68, 79) | 72 (61, 80) | 76 (68, 79) | 0.3 |
| Female sex | 22 (47%) | 10 (50%) | 12 (44%) | 0.7 |
| Race | 0.15 | |||
| black/aa | 5 (11%) | 4 (20%) | 1 (3.7%) | |
| white | 42 (89%) | 16 (80%) | 26 (96%) | |
| Ethnicity | >0.9 | |||
| hispanic/latinx | 1 (2.1%) | 0 (0%) | 1 (3.7%) | |
| not hispanic/latinx | 46 (98%) | 20 (100%) | 26 (96%) | |
| Death | 17 (37%) | 5 (25%) | 12 (46%) | 0.14 |
| Prolonged immunosuppression | 27 (61%) | 0 (0%) | 27 (100%) | <0.001 |
| Number of non-HLA positive beads | 4 (1, 12) | 4 (1, 8) | 11 (4, 17) | 0.2 |
| Hypertension | 44 (94%) | 19 (95%) | 25 (93%) | >0.9 |
| Hyperlipidemia | 39 (83%) | 15 (75%) | 24 (89%) | 0.3 |
| Coronary artery disease | 30 (64%) | 14 (70%) | 16 (59%) | 0.4 |
| Diabetes mellitus | 10 (21%) | 5 (25%) | 5 (19%) | 0.7 |
| Heart failure | 15 (32%) | 5 (25%) | 10 (37%) | 0.4 |
| LGE burden, CMR (% LV mass) | 7 (3, 12) | 9 (0, 14) | 7 (3, 11) | 0.5 |
| LVEF, CMR (%) | 59 (52, 64) | 53 (43, 59) | 63 (58, 65) | 0.004 |
| RVEF, CMR (%) | 52 (48, 56) | 50 (47, 54) | 52 (50, 58) | 0.15 |
| LV wall thickness (AP), mm | 10.00 (8.00, 11.00) | 10.00 (8.00, 12.00) | 10.00 (8.00, 11.00) | 0.5 |
| LV wall thickness (PL), mm | 8.00 (7.00, 10.00) | 8.00 (7.00, 10.00) | 8.00 (7.00, 9.00) | 0.7 |
| Global radial strain, CMR (%) | 26 (21, 36) | 23 (19, 30) | 29 (22, 38) | 0.062 |
| Global circumferential strain, CMR (%) | -17.7 (-20.0, -13.9) | -15.1 (-18.1, -12.9) | -18.2 (-20.8, -14.8) | 0.052 |
| Global longitudinal strain (GLS), CMR (%) | -13.5 (-16.6, -10.7) | -12.5 (-15.1, -9.4) | -13.6 (-17.9, -10.8) | 0.2 |
| Abnormal GLS | 32 (84%) | 15 (94%) | 17 (77%) | 0.4 |
| 1 Median (Q1, Q3); n (%) | ||||
| 2 Wilcoxon rank sum test; Pearson’s Chi-squared test; Fisher’s exact test | ||||